Global and United States Adrenoleukodystrophy Treatment Market Report & Forecast 2022-2028

Table of Contents

1 Study Coverage

• 1.1 Adrenoleukodystrophy Treatment Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million) Introduction
• 1.2 Global Adrenoleukodystrophy Treatment Outlook 2017 VS 2022 VS 2028
  • 1.2.1 Global Adrenoleukodystrophy Treatment Market Size for the Year 2017-2028
  • 1.2.2 Global Adrenoleukodystrophy Treatment Market Size for the Year 2017-2028
• 1.3 Adrenoleukodystrophy Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
  • 1.3.1 The Market Share of United States Adrenoleukodystrophy Treatment in Global, 2017 VS 2022 VS 2028
  • 1.3.2 The Growth Rate of Adrenoleukodystrophy Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
• 1.4 Adrenoleukodystrophy Treatment Market Dynamics
  • 1.4.1 Adrenoleukodystrophy Treatment Industry Trends
  • 1.4.2 Adrenoleukodystrophy Treatment Market Drivers
  • 1.4.3 Adrenoleukodystrophy Treatment Market Challenges
  • 1.4.4 Adrenoleukodystrophy Treatment Market Restraints
• 1.5 Study Objectives
• 1.6 Years Considered

2 Adrenoleukodystrophy Treatment by Type

• 2.1 Adrenoleukodystrophy Treatment Market Segment by Type
  • 2.1.1 Oral Drugs
  • 2.1.2 Parenteral Drugs
• 2.2 Global Adrenoleukodystrophy Treatment Market Size by Type (2017, 2022 & 2028)
• 2.3 Global Adrenoleukodystrophy Treatment Market Size by Type (2017-2028)
• 2.4 United States Adrenoleukodystrophy Treatment Market Size by Type (2017, 2022 & 2028)
• 2.5 United States Adrenoleukodystrophy Treatment Market Size by Type (2017-2028)

3 Adrenoleukodystrophy Treatment by Application

• 3.1 Adrenoleukodystrophy Treatment Market Segment by Application
  • 3.1.1 Hospital
  • 3.1.2 Clinic
  • 3.1.3 Home Care
• 3.2 Global Adrenoleukodystrophy Treatment Market Size by Application (2017, 2022 & 2028)
• 3.3 Global Adrenoleukodystrophy Treatment Market Size by Application (2017-2028)
• 3.4 United States Adrenoleukodystrophy Treatment Market Size by Application (2017, 2022 & 2028)
• 3.5 United States Adrenoleukodystrophy Treatment Market Size by Application (2017-2028)

4 Global Adrenoleukodystrophy Treatment Competitor Landscape by Company

• 4.1 Global Adrenoleukodystrophy Treatment Market Size by Company
  • 4.1.1 Top Global Adrenoleukodystrophy Treatment Companies Ranked by Revenue (2021)
  • 4.1.2 Global Adrenoleukodystrophy Treatment Revenue by Player (2017-2022)
• 4.2 Global Adrenoleukodystrophy Treatment Concentration Ratio (CR)
  • 4.2.1 Adrenoleukodystrophy Treatment Market Concentration Ratio (CR) (2017-2022)
  • 4.2.2 Global Top 5 and Top 10 Largest Companies of Adrenoleukodystrophy Treatment in 2021
  • 4.2.3 Global Adrenoleukodystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 4.3 Global Adrenoleukodystrophy Treatment Headquarters, Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million) Type
  • 4.3.1 Global Adrenoleukodystrophy Treatment Headquarters and Area Served
  • 4.3.2 Global Adrenoleukodystrophy Treatment Companies Revenue in Adrenoleukodystrophy Treatment Business (2017-2022) & (US$ Million) Type
  • 4.3.3 Date of International Companies Enter into Adrenoleukodystrophy Treatment Market
• 4.4 Companies Mergers & Acquisitions, Expansion Plans
• 4.5 United States Adrenoleukodystrophy Treatment Market Size by Company
  • 4.5.1 Top Adrenoleukodystrophy Treatment Players in United States, Ranked by Revenue (2021)
  • 4.5.2 United States Adrenoleukodystrophy Treatment Revenue by Players (2020, 2021 & 2022)

5 Global Adrenoleukodystrophy Treatment Market Size by Region

• 5.1 Global Adrenoleukodystrophy Treatment Market Size by Region: 2017 VS 2022 VS 2028
• 5.2 Global Adrenoleukodystrophy Treatment Market Size by Region (2017-2028)
  • 5.2.1 Global Adrenoleukodystrophy Treatment Market Size by Region: 2017-2022
  • 5.2.2 Global Adrenoleukodystrophy Treatment Market Size by Region (2023-2028)

6 Segment in Region Level & Country Level

• 6.1 North America
  • 6.1.1 North America Adrenoleukodystrophy Treatment Market Size YoY Growth 2017-2028
  • 6.1.2 North America Adrenoleukodystrophy Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.1.3 United States
  • 6.1.4 Canada
• 6.2 Asia-Pacific
  • 6.2.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size YoY Growth 2017-2028
  • 6.2.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
  • 6.2.3 China
  • 6.2.4 Japan
  • 6.2.5 South Korea
  • 6.2.6 India
  • 6.2.7 Australia
  • 6.2.8 China Taiwan
  • 6.2.9 Indonesia
  • 6.2.10 Thailand
  • 6.2.11 Malaysia
• 6.3 Europe
  • 6.3.1 Europe Adrenoleukodystrophy Treatment Market Size YoY Growth 2017-2028
  • 6.3.2 Europe Adrenoleukodystrophy Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.3.3 Germany
  • 6.3.4 France
  • 6.3.5 U.K.
  • 6.3.6 Italy
  • 6.3.7 Russia
• 6.4 Latin America
  • 6.4.1 Latin America Adrenoleukodystrophy Treatment Market Size YoY Growth 2017-2028
  • 6.4.2 Latin America Adrenoleukodystrophy Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.4.3 Mexico
  • 6.4.4 Brazil
  • 6.4.5 Argentina
• 6.5 Middle East and Africa
  • 6.5.1 Middle East and Africa Adrenoleukodystrophy Treatment Market Size YoY Growth 2017-2028
  • 6.5.2 Middle East and Africa Adrenoleukodystrophy Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
  • 6.5.3 Turkey
  • 6.5.4 Saudi Arabia
  • 6.5.5 UAE

7 Company Profiles

• 7.1 bluebird bio
  • 7.1.1 bluebird bio Company Details
  • 7.1.2 bluebird bio Business Overview
  • 7.1.3 bluebird bio Adrenoleukodystrophy Treatment Introduction
  • 7.1.4 bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.1.5 bluebird bio Recent Development
• 7.2 Orpheris
  • 7.2.1 Orpheris Company Details
  • 7.2.2 Orpheris Business Overview
  • 7.2.3 Orpheris Adrenoleukodystrophy Treatment Introduction
  • 7.2.4 Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.2.5 Orpheris Recent Development
• 7.3 MedDay Pharmaceuticals
  • 7.3.1 MedDay Pharmaceuticals Company Details
  • 7.3.2 MedDay Pharmaceuticals Business Overview
  • 7.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
  • 7.3.4 MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.3.5 MedDay Pharmaceuticals Recent Development
• 7.4 MINORYX THERAPEUTICS SL
  • 7.4.1 MINORYX THERAPEUTICS SL Company Details
  • 7.4.2 MINORYX THERAPEUTICS SL Business Overview
  • 7.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Introduction
  • 7.4.4 MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.4.5 MINORYX THERAPEUTICS SL Recent Development
• 7.5 Pfizer
  • 7.5.1 Pfizer Company Details
  • 7.5.2 Pfizer Business Overview
  • 7.5.3 Pfizer Adrenoleukodystrophy Treatment Introduction
  • 7.5.4 Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.5.5 Pfizer Recent Development
• 7.6 Amgen
  • 7.6.1 Amgen Company Details
  • 7.6.2 Amgen Business Overview
  • 7.6.3 Amgen Adrenoleukodystrophy Treatment Introduction
  • 7.6.4 Amgen Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.6.5 Amgen Recent Development
• 7.7 AstraZeneca
  • 7.7.1 AstraZeneca Company Details
  • 7.7.2 AstraZeneca Business Overview
  • 7.7.3 AstraZeneca Adrenoleukodystrophy Treatment Introduction
  • 7.7.4 AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.7.5 AstraZeneca Recent Development
• 7.8 Abbott
  • 7.8.1 Abbott Company Details
  • 7.8.2 Abbott Business Overview
  • 7.8.3 Abbott Adrenoleukodystrophy Treatment Introduction
  • 7.8.4 Abbott Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.8.5 Abbott Recent Development
• 7.9 agtc
  • 7.9.1 agtc Company Details
  • 7.9.2 agtc Business Overview
  • 7.9.3 agtc Adrenoleukodystrophy Treatment Introduction
  • 7.9.4 agtc Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.9.5 agtc Recent Development
• 7.10 ReceptoPharm
  • 7.10.1 ReceptoPharm Company Details
  • 7.10.2 ReceptoPharm Business Overview
  • 7.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Introduction
  • 7.10.4 ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.10.5 ReceptoPharm Recent Development
• 7.11 The Myelin Project
  • 7.11.1 The Myelin Project Company Details
  • 7.11.2 The Myelin Project Business Overview
  • 7.11.3 The Myelin Project Adrenoleukodystrophy Treatment Introduction
  • 7.11.4 The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.11.5 The Myelin Project Recent Development
• 7.12 SOM Biotech
  • 7.12.1 SOM Biotech Company Details
  • 7.12.2 SOM Biotech Business Overview
  • 7.12.3 SOM Biotech Adrenoleukodystrophy Treatment Introduction
  • 7.12.4 SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.12.5 SOM Biotech Recent Development
• 7.13 Viking Therapeutics
  • 7.13.1 Viking Therapeutics Company Details
  • 7.13.2 Viking Therapeutics Business Overview
  • 7.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Introduction
  • 7.13.4 Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.13.5 Viking Therapeutics Recent Development
• 7.14 Nutra Pharma Corporation
  • 7.14.1 Nutra Pharma Corporation Company Details
  • 7.14.2 Nutra Pharma Corporation Business Overview
  • 7.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Introduction
  • 7.14.4 Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.14.5 Nutra Pharma Corporation Recent Development
• 7.15 Genetix Biotech
  • 7.15.1 Genetix Biotech Company Details
  • 7.15.2 Genetix Biotech Business Overview
  • 7.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Introduction
  • 7.15.4 Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.15.5 Genetix Biotech Recent Development
• 7.16 Magenta Therapeutics
  • 7.16.1 Magenta Therapeutics Company Details
  • 7.16.2 Magenta Therapeutics Business Overview
  • 7.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Introduction
  • 7.16.4 Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.16.5 Magenta Therapeutics Recent Development
• 7.17 NeuroVia
  • 7.17.1 NeuroVia Company Details
  • 7.17.2 NeuroVia Business Overview
  • 7.17.3 NeuroVia Adrenoleukodystrophy Treatment Introduction
  • 7.17.4 NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.17.5 NeuroVia Recent Development
• 7.18 Novartis
  • 7.18.1 Novartis Company Details
  • 7.18.2 Novartis Business Overview
  • 7.18.3 Novartis Adrenoleukodystrophy Treatment Introduction
  • 7.18.4 Novartis Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.18.5 Novartis Recent Development
• 7.19 CELGENE CORPORATION
  • 7.19.1 CELGENE CORPORATION Company Details
  • 7.19.2 CELGENE CORPORATION Business Overview
  • 7.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Introduction
  • 7.19.4 CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.19.5 CELGENE CORPORATION Recent Development
• 7.20 Jazz Pharmaceuticals
  • 7.20.1 Jazz Pharmaceuticals Company Details
  • 7.20.2 Jazz Pharmaceuticals Business Overview
  • 7.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
  • 7.20.4 Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.20.5 Jazz Pharmaceuticals Recent Development
• 7.21 Sanofi
  • 7.21.1 Sanofi Company Details
  • 7.21.2 Sanofi Business Overview
  • 7.21.3 Sanofi Adrenoleukodystrophy Treatment Introduction
  • 7.21.4 Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
  • 7.21.5 Sanofi Recent Development

8 Research Findings and Conclusion

9 Appendix

• 9.1 Research Methodology
  • 9.1.1 Methodology/Research Approach
  • 9.1.2 Data Source
• 9.2 Author Details